Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Post-Mkt 12-22 18:17:46 EST

6.47

+0.42

+6.94%

盘后6.49

+0.02+0.31%

17:42 EST

High6.48	Low5.86	Vol1.72M
Open5.98	D1 Closing6.05	Amplitude10.25%
Mkt Cap1.32B	Tradable Cap744.05M	Total Shares203.47M
T/O10.98M	T/O Rate1.50%	Tradable Shares115.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":6.47,"timestamp":1766437200000,"preClose":6.05,"halted":0,"volume":1721963,"hourTrading":{"tag":"盘后","latestPrice":6.49,"preClose":6.47,"latestTime":"17:42 EST","volume":37464,"amount":242392.192392,"timestamp":1766443347549},"delay":0,"floatShares":114999999,"shares":203467845,"eps":-0.535012,"marketStatus":"Post-Mkt","change":0.42,"latestTime":"12-22 18:17:46 EST","open":5.98,"high":6.48,"low":5.86,"amount":10977697.1696669,"amplitude":0.102479,"askPrice":6.55,"askSize":3,"bidPrice":6.35,"bidSize":190,"shortable":3,"etf":0,"ttmEps":-0.535012,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.05,"preHourTrading":{"tag":"盘前","latestPrice":5.97,"preClose":6.05,"latestTime":"09:25 EST","volume":14446,"amount":89401.9081944,"timestamp":1766413500019},"postHourTrading":{"tag":"盘后","latestPrice":6.49,"preClose":6.47,"latestTime":"17:42 EST","volume":37464,"amount":242392.192392,"timestamp":1766443347549},"volumeRatio":0.246403,"impliedVol":2.1808,"impliedVolPercentile":0.812},"requestUrl":"/m/hq/s/SVRA/wiki","defaultTab":"wiki","newsList":[{"id":"2593388304","title":"Savara Resubmits MOLBREEVI BLA to FDA and Requests Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2593388304","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593388304?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:31","pubTimestamp":1766410292,"startTime":"0","endTime":"0","summary":"Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, has resubmitted its Biologics License Application  to the U.S. Food and Drug Administration  for MOLBREEVI  for the potential treatment of autoimmune pulmonary alveolar proteinosis . The resubmission names FUJIFILM Biotechnologies as the drug substance manufacturer, and Savara has requested Priority Review of the application. MOLBREEVI has previously been granted Fast Track and Breakthrough Therapy Designations by the FDA, Orphan Drug Designation by both the FDA and the European Medicines Agency , and Innovation Passport and Promising Innovative Medicine designations by the UK's Medicines and Healthcare Products Regulatory Agency  for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5rwC0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2593480709","title":"Savara Resubmits the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593480709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593480709?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:30","pubTimestamp":1766410201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA56XFMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2592697061","title":"Savara Inc. : Wells Fargo Raises Target Price to $9 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2592697061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592697061?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:25","pubTimestamp":1766057159,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nAZN4RGSUK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2590516513","title":"Savara Inc. Announces EPO Intention to Grant Patent for Liquid Formulation of MOLBREEVI","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516513","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516513?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458324,"startTime":"0","endTime":"0","summary":"Savara Inc. announced that the European Patent Office has notified the company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis . The liquid formulation and drug-device patents are expected to provide protection in Europe through March 2041 and March 2043, respectively. MOLBREEVI has also received multiple regulatory designations, including Orphan Drug status in both the U.S. and Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire  on December 11, 2025, and is solely responsible for the inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL75PfVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2590451655","title":"Savara Announces European Patent Office (Epo) Intends to Grant a Patent for the Liquid Formulation of Molbreevi*","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590451655?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA35NL3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2588055911","title":"Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055911","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055911?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:22","pubTimestamp":1764681746,"startTime":"0","endTime":"0","summary":"Savara Inc. has released a corporate presentation detailing its ongoing efforts to develop new therapies for rare respiratory diseases, with a primary focus on autoimmune pulmonary alveolar proteinosis . The presentation highlights the company's lead investigational candidate, MOLBREEVI , which currently has conditional trade name acceptance from regulatory authorities but is not yet approved for any indication. Savara plans to resubmit a Biologics License Application  for MOLBREEVI in December 2025, following data that indicate a favorable benefit/risk profile and good tolerability. The presentation also provides insights into the patient journey, emphasizing the challenges of current treatment options such as whole lung lavage and the need for alternative therapies. The executive leadership team and their respective roles are outlined within the document. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL1vhGmM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2588741053","title":"Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2588741053","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588741053?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680715,"startTime":"0","endTime":"0","summary":"Savara Inc. and PARI have been granted a European patent  covering the combination of Savara's investigational therapy, MOLBREEVI, and PARI's optimized eFlow Nebulizer System for aerosolizing the liquid solution. The patent provides protection for the drug-device combination through March 2043. MOLBREEVI, which is being developed for the treatment of autoimmune pulmonary alveolar proteinosis , has received several regulatory designations in the US, EU, and UK. Upon approval, the eFlow Nebulizer System is expected to be marketed as the Vespera Nebulizer System for use with MOLBREEVI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire  on December 0","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL1qkbPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2588082687","title":"BUZZ-India's Mastek rises on report of promoters considering stake sale at premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082687","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588082687?lang=en_us&edition=fundamental","pubTime":"2025-12-02 14:45","pubTimestamp":1764657905,"startTime":"0","endTime":"0","summary":"BUZZ-India's Mastek rises on report of promoters considering stake sale at premium** Mastek MAST.NS rises as much as 5.8% to 2,318 rupees; set to snap three straight sessions of losses** Technology solutions provider's promoters exploring sale of ~20% stake, per CNBC-TV18 report** Promoters seeking up to 25% premium over current market price, report adds** Stock rated \"buy\" on average; median PT at 2,757.5 rupees, per data compiled by LSEG** MAST last up 1.6%, taking YTD losses to 25.5%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL6N3X80B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2585191112","title":"Master Tec Appoints Chong Peng Khang As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2585191112","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585191112?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:11","pubTimestamp":1763723463,"startTime":"0","endTime":"0","summary":"Nov 21 (Reuters) - Master Tec Group Bhd ::*APPOINTMENT OF CHONG PENG KHANG AS CFO*Further company coverage: MAST.KL* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 21-NOV-202510:55:51 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nRSD685LcW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2585111492","title":"Master Tec Group Posts Qtrly Profit Attributable 8.6 Million RGT","url":"https://stock-news.laohu8.com/highlight/detail?id=2585111492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585111492?lang=en_us&edition=fundamental","pubTime":"2025-11-21 18:42","pubTimestamp":1763721766,"startTime":"0","endTime":"0","summary":"Nov 21 (Reuters) - Master Tec Group Bhd ::*QTRLY PROFIT ATTRIBUTABLE 8.6 MILLION RGT*QTRLY REVENUE 115.8 MILLION RGT  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 21-NOV-202509:14:39.873 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nRSD6lYjVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2585157703","title":"Savara Inc. to Participate in Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157703","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157703?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:06","pubTimestamp":1763672784,"startTime":"0","endTime":"0","summary":"Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and at the Evercore ISI 8th Annual Healthcare Conference on December 4, 2025. Members of the management team will also host one-on-one meetings at these events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9FnQj3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA","BK4127","PIPR"],"gpt_icon":0},{"id":"2584432924","title":"Savara Q3 Net Income USD -29.561 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584432924","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584432924?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573295,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Savara Q3 income from operations USD -30.255 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:01:00.197 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1N1X8l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2584607024","title":"Savara Inc. Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584607024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584607024?lang=en_us&edition=fundamental","pubTime":"2025-11-18 11:54","pubTimestamp":1763438072,"startTime":"0","endTime":"0","summary":"Savara ( ($SVRA) ) has released its Q3 earnings. Here is a breakdown of the information Savara presented to its investors. Savara Inc. is a clinica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/savara-inc-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/savara-inc-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2583506655","title":"Exploring High Growth Tech Stocks in the US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506655?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:08","pubTimestamp":1763118488,"startTime":"0","endTime":"0","summary":"The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","KNSA","SVRA","GYRE","BK4505"],"gpt_icon":0},{"id":"2583912655","title":"Savara Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583912655","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583912655?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:10","pubTimestamp":1763046600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 10:10 ET (15:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2583583677","title":"Savara Q3 EPS $(0.14) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583677","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583677?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:21","pubTimestamp":1762982514,"startTime":"0","endTime":"0","summary":"Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 5.26 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48819679/savara-q3-eps-0-14-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","NQmain","SQQQ","BK4139","TQQQ","QID",".IXIC","USAW.SI","MNQmain","USJW.SI","TSYW.SI","PSQ","SVRA","QLD"],"gpt_icon":0},{"id":"2583583636","title":"Savara Inc. Unveils Corporate Presentation on New Therapies for Rare Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2583583636","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583583636?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:19","pubTimestamp":1762982395,"startTime":"0","endTime":"0","summary":"Savara Inc. has released a corporate presentation detailing its ongoing efforts to develop new therapies for rare respiratory diseases, with a particular focus on autoimmune pulmonary alveolar proteinosis . The company highlighted the challenges faced by patients, including frequent misdiagnosis and the current reliance on whole lung lavage as the primary treatment option. Savara is advancing MOLBREEVI , which has been conditionally accepted as a trade name by the FDA and EMA, though it is not yet approved for any indication. The company plans to resubmit its Biologics License Application  in December 2025. The executive leadership team, including CEO Matthew Pauls, is overseeing these initiatives. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3gmGGy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2583917588","title":"Savara Inc. posts Q3 net loss of $29.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583917588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583917588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:08","pubTimestamp":1762981695,"startTime":"0","endTime":"0","summary":"Savara Inc. reported a net loss of $29.6 million, or $ per share, for the third quarter of 2025, compared with a net loss of $24.2 million, or $ per share, for the same period in 2024. Research and development expenses rose by 1.4% to $20.6 million, primarily due to activities related to the MOLBREEVI program. General and administrative expenses increased by 60.1% to $9.6 million, mainly due to higher personnel costs and commercial activities. As of September 30, 2025, Savara had cash, cash equivalents, and short-term investments of approximately $124.4 million and debt of about $29.8 million. The company recently raised about $140 million through an equity financing and announced a $75 million royalty funding agreement. Savara expects to resubmit the Biologics License Application for MOLBREEVI in December 2025 and to submit marketing authorization applications in Europe and the UK in the first quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbXNqTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2583883785","title":"BRIEF-Savara Q3 Net Income USD -29.561 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583883785","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583883785?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981547,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Q3 Net Income USD -29.561 Million\n\n\nNov 12 (Reuters) - Savara Q3 income from operations USD -30.255 million.\n\nQ3 operating expenses USD 30.255 million\nQ3 EPS USD -0.14","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX2A3968:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2583588889","title":"Savara Q3 EPS USD -0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588889?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX2A3968:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com;www.masttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1257},{"period":"1month","weight":0.3152},{"period":"3month","weight":0.7139},{"period":"6month","weight":1.9369},{"period":"1year","weight":0.8731},{"period":"ytd","weight":0.9707}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.121255},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051283},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.01131},{"month":4,"riseRate":0.615385,"avgChangeRate":0.035184},{"month":5,"riseRate":0.692308,"avgChangeRate":0.023552},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.033774},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.023739},{"month":8,"riseRate":0.538462,"avgChangeRate":0.016257},{"month":9,"riseRate":0.538462,"avgChangeRate":0.011115},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.136764},{"month":11,"riseRate":0.538462,"avgChangeRate":0.131385},{"month":12,"riseRate":0.538462,"avgChangeRate":0.220075}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction